These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3180739)

  • 1. C4-mediated inhibition of immune precipitation and differences in inhibitory action of genetic variants, C4A3 and C4B1.
    Paul L; Skanes VM; Mayden J; Levine RP
    Complement; 1988; 5(3):110-9. PubMed ID: 3180739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fluid-phase binding of human C4 and its genetic variants, C4A3 and C4B1, to immunoglobulins.
    Kishore N; Shah D; Skanes VM; Levine RP
    Mol Immunol; 1988 Sep; 25(9):811-9. PubMed ID: 3264881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding to erythrocyte complement receptor type 1 of BSA/anti-BSA complexes opsonized by C4A3 or C4B1 in the presence of serum.
    Klint C; Truedsson L; Sturfelt G
    Scand J Immunol; 1995 Oct; 42(4):425-32. PubMed ID: 7569775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the metabolism of C4 isotypes in patients with complement activation.
    Peake PW; Pussell BA; Charlesworth JA; Gavrilovic L; Timmermans V
    Clin Exp Immunol; 1989 Oct; 78(1):49-53. PubMed ID: 2530015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of C1, C1-inactivator and C4 in modulating immune precipitation.
    Schifferli JA; Steiger G; Schapira M
    Clin Exp Immunol; 1985 Jun; 60(3):605-12. PubMed ID: 4017288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of C4 null alleles on C4 activation in systemic lupus erythematosus.
    Briggs DC; Senaldi G; Isenberg DA; Welsh KI; Vergani D
    Ann Rheum Dis; 1991 Apr; 50(4):251-4. PubMed ID: 2029208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two isotypes of human C4, C4A and C4B have different structure and function.
    Schifferli JA; Paccaud JP
    Complement Inflamm; 1989; 6(1):19-26. PubMed ID: 2650988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional properties of heterogeneous human asialo-C4 and its isotypes C4A and C4B.
    Schultz DR; Arnold PI
    Immunobiology; 1992 Jun; 185(1):90-102. PubMed ID: 1398744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relative roles of C4A and C4B in prevention of immune precipitation, solubilisation and immune adherence.
    Holme ER; Veitch J; Johnston A; McKay IC; Whaley K
    Rheumatol Int; 1992; 12(5):187-90. PubMed ID: 1290020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difference in the biological properties of the two forms of the fourth component of human complement (C4).
    Schifferli JA; Steiger G; Paccaud JP; Sjöholm AG; Hauptmann G
    Clin Exp Immunol; 1986 Feb; 63(2):473-7. PubMed ID: 3486068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between C4A and C4B in the handling of immune complexes: the enhancement of CR1 binding is more important than the inhibition of immunoprecipitation.
    Gatenby PA; Barbosa JE; Lachmann PJ
    Clin Exp Immunol; 1990 Feb; 79(2):158-63. PubMed ID: 2138067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal variations in complement activation and deposition of C3b and C4b on model immune complexes.
    Yokoyama I; Waxman F
    Immunology; 1993 Oct; 80(2):168-76. PubMed ID: 8262546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of the disease-associated complement C4 gene from the HLA-A1, B8, DR3 haplotype.
    Ulgiati D; Abraham LJ
    Exp Clin Immunogenet; 1996; 13(1):43-54. PubMed ID: 8854088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement-mediated adherence of immune complexes to human erythrocytes. Difference in the requirements for C4A and C4B.
    Schifferli JA; Hauptmann G; Paccaud JP
    FEBS Lett; 1987 Mar; 213(2):415-8. PubMed ID: 3493921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
    Doekes G; van Es LA; Daha MR
    Immunology; 1983 Jun; 49(2):215-22. PubMed ID: 6852866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
    Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).
    Schifferli JA; Steiger G; Paccaud JP
    Clin Exp Immunol; 1986 May; 64(2):407-14. PubMed ID: 3488858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of antibody isotype on the activation of C3 and C4 by immune complexes formed in the presence of serum: correlation with the prevention of immune precipitation.
    Stewart WW; Johnson A; Steward MW; Whaley K; Kerr MA
    Mol Immunol; 1990 May; 27(5):423-8. PubMed ID: 2366759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence showing that the 1105 and 1106 isotypic residues of the fourth component of human complement, C4A, are not involved in amide bond formation.
    Reilly BD; Skanes VM; Levine RP
    Mol Immunol; 1994 Jul; 31(10):761-9. PubMed ID: 7518568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.